This is a working overview of modified GRF(1-29), written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-06. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
The extracted DNA should be stored for as short a time as possible, and the conditions for storage should be chosen to minimize the risk of degradation. In general, the extracted DNA should be stored under the best possible conditions to ensure its stability and integrity for downstream applications.
On the same day as the 2019–20 state budget, Pritzker signed the "Fair Tax" law, which offered a constitutional amendment to voters in the November 2020 election to replace Illinois's flat tax with graduated rates. He promised that income taxes would not increase for Illinoisans who make $250,000 a year or less, who are 97% of the state's wage earners. Pritzker and his supporters said changing income tax laws was the first step toward comprehensive state tax reform. According to the governor's office, under this proposal, families and couples would see tax cuts across the board. For example, a family of four making $61,000 a year would pay $41 less in income tax before any other tax exemptions or deductions. Moreover, there would be a tax credit of up to $100 per child for individuals making less than $80,000 and joint filers earning under $100,000. The corporate tax rate would rise from 7% to 7.95%, equal to the highest personal rate. In addition, Pritzker wanted to increase the property tax credit to 6% from 5%. Pritzker donated more than $55 million to "Vote Yes for Fairness", a committee that supported the tax change. The tax change set up a fight between Pritzker and Ken Griffin, who donated over $50 million to a group opposing it. Griffin called Pritzker "spineless", accusing him of trying "to sell a trick disguised as a solution", and pointed to Pritzker's offshore trusts and personal tax avoidance schemes as hypocritical. Pritzker claimed that his income tax proposal would bring $3.4 billion in tax revenue.
The paratroopers took control of Ghazni from the Polish Armed Forces, allowing the Polish Task Force White Eagle (pl:Polski Kontyngent Wojskowy w Afganistanie) to consolidate around the provincial seat in northern Ghazni. In June 2012, the 3rd Brigade Combat Team deployed as part of the Global Response Force (GRF) in support of heavy combat operations conducted by the 1st Infantry Division. The Brigade was spread across much of RC-East Afghanistan. In December 2013, elements of the 4th Brigade deployed again to Afghanistan and they were joined by the 1st Brigade in spring 2014. Since 11 September 2001, the division has lost 106 paratroopers in Afghanistan and 139 paratroopers in Iraq.
Sources: en.wikipedia.org
Decreasing reactant stability: Houk has proposed that differences in the energy (Ed ‡) required to distort the azide and alkyne into the transition state geometries control the barrier heights for the reaction. The activation energy (E ‡) is the sum of destabilizing distortions and stabilizing interactions (Ei ‡). The most significant distortion is in the azide functional group with lesser contribution of alkyne distortion. However, it is only the cyclooctyne that can be easily modified for higher reactivity. Calculated barriers of reaction for phenyl azide and acetylene (16.2 kcal/mol) versus cyclooctyne (8.0 kcal/mol) results in a predicted rate increase of 106. The cyclooctyne requires less distortion energy (1.4 kcal/mol versus 4.6 kcal/mol) resulting in a lower activation energy despite smaller interaction energy.
=== Units === Mass concentration (g/dL or g/L) is the most common measurement unit in the United States. Is usually given with dL (decilitres) as the denominator in the United States, and usually with L (litres) in, for example, Sweden. Molar concentration (mol/L) is used to a higher degree in most of the rest of the world, including the United Kingdom and other parts of Europe and Australia and New Zealand. International units (IU) are based on measured biological activity or effect, or for some substances, a specified equivalent mass. Enzyme activity (kat) is commonly used for e.g. liver function tests like AST, ALT, LD and γ-GT in Sweden. Percentages and time-dependent units (mol/s) are used for calculated derived parameters, e.g. for beta cell function in homeostasis model assessment or thyroid's secretory capacity.
=== Drug target === POMC is a pharmacological target for obesity treatment. The combination drug naltrexone/bupropion acts on hypothalamic POMC neurons to reduce appetite and food intake. In rare cases of POMC deficiency, treatment with setmelanotide, a selective melanocortin-4 receptor agonist, has been effective. Two individuals with confirmed POMC deficiency showed clinical improvement following this therapy.
To import or export, sell or offer for sale, supply—even gratuitously—transport, carry, keep in storage, store, administer, or in any way deliver for consumption any narcotic substance, without authorization or in violation of legal or regulatory provisions. This article rendered these drugs illegal and thus authorized police powers and regulatory bodies to impose sanctions on users and traffickers of illicit drugs. Even before their legal prohibition, narcotic drugs were already shrouded in prejudice—particularly racial prejudice, such as in the case of marijuana, which was nicknamed "Angola weed", because it was mainly used by adherents of Afro-Brazilian religions in their rituals. In 1973, when Brazil acceded to the Convention on Psychotropic Substances, the "war on drugs" shifted its approach; the new drug policies clearly defined the penalties and consequences associated with possessing, purchasing, or selling these substances. It was in the Brazilian state's interest to marginalize and prohibit narcotics, given that during the 1968 student marches against the military dictatorship, drugs had been used as a symbol of resistance against the regime—and, due to the lack of clear penalties, users faced neither prosecution nor punishment.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.